USUjjawal Kumar Shriwastav

Ujjawal Kumar Shriwastav

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ujjawal Kumar Shriwastav has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin for Muscle-Invasive Bladder Cancer: Real-World Feasibility and Safety in a Resource-Constrained Setting

    by Deepak Sundriyal, Sai Prasath, Harsha S. Prakash, Anusha Mruthyunjaya Swamy, Karthik Jayalingappa, Mayank Kapoor, Mahesh Koulagi, Deepa Joseph, Sweety Gupta, Parmod Kumar, et al.

    PURPOSE: Muscle-invasive bladder carcinoma (MIBC) poses major treatment challenges in low- and middle-income countries because of logistical and socioeconomic barriers limiting neoadjuvant chemotherapy (NAC) delivery. While dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) improves pathologic response and survival over gemcitabine-cisplatin, its multiday schedule reduces practicality. Accelerated MVAC (AMVAC), a single-day outpatient regimen, may offer a feasible alternative. This study evaluated the feasibility and safety of AMVAC in Indian patients with MIBC. METHODS: We conducted a single-arm feasibility study at the All India Institute of Medical Sciences, Rishikesh, India, between December 2021 and November 2024. Adults with stage II-III MIBC and cisplatin eligibility received 3-4 cycles of single-day AMVAC with pegfilgrastim support before radical cystectomy. Feasibility was defined as completion of ≥3 or 4 cycles within protocol-specified timeframes. Toxicities were graded using CTCAE v5.0, and outcomes were analyzed descriptively. RESULTS: Sixty patients were enrolled (mean age 55.2 ± 11.2 years; 90% male); 55 received neoadjuvant, and five adjuvant therapy. The mean number of chemotherapy cycles delivered was 3.87 ± 0.85. Feasibility outcomes were favorable, with 91.6% completing three and 76.6% completing four cycles within protocol timelines. Dose reductions for grade ≥3 toxicities were required in 13 patients (21.7%), whereas four patients discontinued treatment because of reduced creatinine clearance. Grade 3 adverse events occurred in 38.3%, most commonly anemia (16.7%), fatigue, and mucositis (13.3% each). Among neoadjuvant recipients undergoing cystectomy (n = 40), pathologic complete response (PCR) was achieved in 32.5% and pathologic downstaging was achieved in 55%. CONCLUSION: Single-day AMVAC is a feasible and tolerable NAC regimen in a resource-constrained setting, with encouraging PCR and manageable toxicity.

  • Characterization of anemia and its association with functional status and depression in geriatric patients with solid organ cancers

    by Neethu Sunny, Deepak Sundriyal, Ujjawal Kumar Shriwastav, Mridul Khanna, Minakshi Dhar

    Purpose The ongoing demographic transition toward an aging population is accompanied by a rising number of geriatric patients with cancer. Anemia is a common finding in older patients with malignancy. This study aimed to evaluate the prevalence of anemia and its association with functional status and depression among treatment-naïve geriatric patients with solid organ cancer (SOC). Methods In this observational study, geriatric patients with SOC underwent screening for anemia and a comprehensive geriatric assessment (CGA). Those with anemia were further evaluated with iron studies, stool for occult blood, upper and lower gastrointestinal endoscopies, serum B12 and folate levels, Coombs test, serum lactate dehydrogenase levels, and a bone marrow examination, as appropriate. Descriptive statistics (mean, median, and standard deviation), Pearson’s chi-square test, Fisher’s exact test, Kruskal–Wallis test, and Wilcoxon-Mann–Whitney U test were used to analyze the data. Results One hundred and seventy-six patients were included. The median age was 67 (range 60–94) years, with a male preponderance of 76.7% (n = 135) and a stage IV, 81.8% (N = 144) disease. Anemia was detected in 51.7% (n = 91) of patients, with 51.6% (n = 47) having grade 2 severity. Iron deficiency anemia (IDA), functional IDA, possible functional IDA, and no iron deficiency (NID) were found in 23.1% (n = 21), 44% (n = 40), 12.1% (n = 11), and 16.5% (n = 15) of the patients, respectively. We found a significant association of anemia with body-mass index (P = 0.017), performance status (P < 0.005), activities of daily living (P < 0.010), instrumental activities of daily living in males (P < 0.034), balance and mobility (P = 0.016), and depression (P < 0.001). Conclusion More than half of the geriatric patients with SOC were anemic at presentation, with functional IDA being the most common subtype, followed by IDA. Anemia was significantly associated with poorer functional status, impaired mobility and balance, and higher rates of depression, underscoring its substantial impact on both the physical and psychological well-being of older patients with cancer. These findings highlight the importance of comprehensive geriatric assessment and detailed characterization of anemia subtypes, including IDA, functional IDA, possible functional IDA, and NID, as management strategies may vary according to iron status.

  • Open Access

    Prolonged Remission in Metastatic Ano‐Rectal Malignant Melanoma With Single Agent Temozolomide

    by Anusha Mruthyunjaya Swamy, Deepak Sundriyal, Mayank Kapoor, Mridul Khanna, Ravi Hari Phulware, Kranthi Kumar Jandrasupalli, Ujjawal Shriwastav, Amit Sehrawat

    Introduction: With the use of immune checkpoint inhibitors (ICIs) and targeted therapies, the clinical outcomes of metastatic melanoma have drastically improved. The current scenario has reduced the use of chemotherapy as a first‐line treatment. We report an interesting case of a patient with stage IV ano‐rectal canal malignant melanoma with an exceptional response to single‐agent temozolomide.Case Report: We diagnosed a 55‐year‐old female with stage IV anorectal melanoma, BRAF V600 mutation negative. Owing to her poor performance status (PS) and non‐affordability of immunotherapy, after informed decision‐making, she was started on single agent, temozolomide. She achieved a complete metabolic response and sustained it for 3 years and continues to do so with the first‐line single‐agent temozolomide.Conclusion: In a resource‐limited setting, where access to ICIs and targeted therapies is not feasible, and in patients who fail to tolerate these therapies, oral chemotherapy continues to remain effective and is worth trying in patients with poor PS.

  • Open Access

    Sustained Remission With Atezolizumab in a Frail, Geriatric Patient With Advanced‐Stage Large Cell Neuroendocrine Carcinoma Lung

    by Mayank Kapoor, Praneet Bedi, Deepak Sundriyal, Ashita Jain, Ujjawal Shriwastav, Amit Sehrawat

    Large cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive cancer primarily found in the lungs but can also occur in other organs. It is characterized by rapid progression and high metastatic potential. We present a case of advanced‐stage LCNEC lung in a patient with a poor performance status (PS), requiring oxygen support. Imaging revealed a large right upper lobe mass, lymphadenopathy, with bronchial encasement and invasion into the superior vena cava, leading to SVC syndrome and pleural effusion. Biopsy and immunohistochemistry confirmed LCNEC. Due to the patient’s poor PS, treatment began with low‐dose single‐agent chemotherapy (carboplatin), followed by etoposide and cisplatin after improvement. Local radiation was also administered, and the treatment plan was adjusted to include atezolizumab. After 10 cycles, the patient achieved complete remission, sustained for 6 years. This case highlights the complexities of managing advanced LCNEC in a geriatric patient and the effectiveness of a multidisciplinary approach and immunotherapy.

  • High Prevalence of Malnutrition in Geriatric Patients With Solid Organ Cancer—An Institutional Study

    by Ujjawal Kumar Shriwastav, Deepak Sundriyal, Mridul Khanna, Neethu Sunny, Amit Sehrawat, Minakshi Dhar

    PURPOSE: The demographic transition toward aging heralds an increase in the number of geriatric patients with cancer in India. Comprehensive geriatric assessment (CGA) is a sine qua non for treatment planning and shared decision making in these patients. We aimed to study the prevalence of malnutrition and the associated risk factors in geriatric patients with solid organ cancer. METHODS: In this observational study, treatment-naïve geriatric patients with cancer underwent CGA. We performed a Mini Nutritional Assessment (MNA) to diagnose malnutrition. Data analysis was done using descriptive statistics, Pearson’s chi-square, Spearman correlation, and multivariable regression analysis to assess the factors associated with malnutrition. RESULTS: One hundred forty-two patients were included in the analysis. The median age was 67 (range, 60-88) years, with a male preponderance of 73.2% (n = 104) and a stage IV disease of 75.4% (n = 107). Most patients, 91.6% (n = 130), had abnormal MNA scores. Nearly one third of the patients, 35.2% (n = 50), were underweight (BMI 2 ). Poor performance status (PS) was seen in 66.2% (n = 94) of the patients. Poor appetite 79.6% (n = 113) was the most common risk factor, followed by addictions (74.6%, n = 106), chronic constipation (35.9%, n = 51), and polypharmacy (21.8%, n = 31). Cognitive impairment and depression were seen in 35.2% (n = 50) and 57.1% (n = 81) of the patients, respectively. The study found a significant correlation of MNA with age ( P = .048), depression ( P < .001), PS ( P < .001), functional decline ( P < .001), and cognition ( P < .001). CONCLUSION: There exists a widespread prevalence of malnutrition and amenable risk factors in geriatric patients with cancer. Nutritional assessment is essential, and interventions should be implemented to improve clinical outcomes.


  • Open Access

    Hodgkin Lymphoma Presenting as Pel–Ebstein Fever: A Case Report

    by Ujjawal Kumar Shriwastav, Deepak Sundriyal, Parmod Kumar, Amit Sehrawat

    Background: Prolonged fever of more than a year duration can be a symptom of underlying malignancy. This article appreciates the need for diligent history taking and carefully performed clinical examination, which is fundamental to reaching an initial diagnosis.Case: We report the case of a middle‐aged male who presented to us with a fever of more than a year duration. The patient's residence was located in a remote area where the nearby tertiary care center was almost 250 km away. He was empirically treated with antibiotics without any success by local physicians. After more than a year, he reported to us and was diagnosed with Hodgkin lymphoma with a characteristic Pel–Ebstein pattern of fever missed earlier by the local physicians. His fever resolved within 5 days of chemotherapy, and he achieved complete remission.Conclusion: Meticulous history‐taking and clinical examination are essential for reaching a clinical diagnosis. Malignant causes should be considered in the differentials of prolonged fever.

  • Open Access

    Factors Associated With Default of Treatment and Follow-Up Among Patients With Cancer: A Cross-Sectional Study From a Lower-Middle-Income Country

    by Deepak Sundriyal, Mayank Kapoor, Preeti Antil, Sweety Gupta, Parmod Kumar, Ujjawal Kumar Shriwastav, Amit Sehrawat

    PURPOSE: Desirable outcomes during the treatment of patients with cancer require adherence to evaluation, treatment, and follow-up. This study aimed to evaluate the factors associated with default in patients with cancer. MATERIALS AND METHODS: We included patients with a histologically confirmed diagnosis of cancer who defaulted during evaluation, treatment, and follow-up. All patients’ detailed demographic and clinical data were recorded. Those lost to follow-up were interviewed telephonically. The factors associated with default were noted. Descriptive statistics were used to compute the demographic and clinical characteristics. RESULTS: In total, 172 patients were included. Geriatric and female patients were 38.9% and 37.2%, respectively. Fifty-eight percent of the patients lived in rural areas, whereas 45.9% were illiterate. More than one third (34.3%) of the patients who defaulted received the curative-intent treatment, whereas 62.1% of patients had a good performance status immediately before default. The average distance traveled by the patients to reach the cancer facility was 143 ± 13.15 km. The most common reasons for default were the lack of social support, financial constraints, difficulty in commuting, and too sick to come in 45 (26.2%), 35 (20.3%), 28 (16.3%), and 23 (13.4%) patients, respectively. Twenty-nine (16.9%) patients reported more than one reason for default. CONCLUSION: Lack of social support, financial constraints, transportation barriers, and inadequate counseling by the health care provider serve as barriers to uninterrupted cancer care. These factors are often interrelated and can be attenuated by adopting the hub and spoke model. Simultaneously, a good relationship between the patient and the health care provider fostered by appropriate counseling is imperative to increase adherence to cancer treatment and improve the outcome.


  • Open Access

    Prolonged remission in metastatic ano-rectal malignant melanoma with single agent temozolomide

    by Anusha Mruthyunjaya Swamy, Deepak Sundriyal, Mayank Kapoor, Mridul Khanna, Ravi Hari Phulware, Kranthi Kumar Jandrasupalli, Ujjawal Kumar Shriwastav, Amit Sehrawat

    With the use of Immune Checkpoint Inhibitors (ICIs) and targeted therapies, the clinical outcomes of metastatic melanoma have drastically improved. The current scenario has reduced the use of chemotherapy as a first-line treatment. However, in a resource-limited setting, where access to ICIs and targeted therapies is not feasible, and in patients who fail to tolerate these therapies, chemotherapy continues to remain effective. The median survival and response rates with chemotherapy alone are dismally low. Here, we report a case in which a patient with stage IV anorectal melanoma was able to achieve a complete metabolic response and sustain it for 3 years and continue to do so with the first-line single-agent temozolomide.